Evidence map›Paper›PMID 40606500›Full record

ArticleFrontiers in human neuroscience2025

Serum lipidomic analysis identifies potential therapeutic targets for neurodegeneration.

Lumi Zhang, Duanbin Li, Na Zhao, Guoping Peng

Abstract read
In one paragraph

Article in Frontiers in human neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Lumi Zhang *Department of Neurology, Wenzhou TCM Hospital of Zhejiang Chinese Medical University, Wenzhou, China.
Duanbin Li *Department of Cardiology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Na ZhaoDepartment of Neurology, Wenzhou TCM Hospital of Zhejiang Chinese Medical University, Wenzhou, China.
Guoping PengDepartment of Neurology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Circulating very-long-chain saturated fatty acids (VLSFAs) may attenuate age-related cognitive decline, but their direct association with neurodegeneration biomarkers and the underlying mechanisms remain unclear. Methods: This cross-sectional study examined associations between circulating fatty acid profiles, neurodegeneration (assessed by serum neurofilament light chain, NfL), cognitive function, and hypertension in 1,677 U.S. adults from the National Health and Nutrition Examination Survey (NHANES) 2013-2014. Advanced statistical methods including weighted quantile sum (WQS) regression, Bayesian kernel machine regression (BKMR), quantile g-computation (Qgcomp), and formal mediation analyses were employed. Results: The VLSFA mixture demonstrated significant inverse associations with serum NfL (β = -0.044, 95% CI: -0.076, -0.011) and the prevalence of hypertension (OR = 0.788, 95% CI: 0.672, 0.923). This association with NfL was non-linear, exhibiting a more pronounced protective effect at lower VLSFA concentrations. Higher VLSFA levels were significantly correlated with better cognitive performance, particularly in processing speed (Digit-Symbol Substitution Test) and memory (delayed recall). Hypertension was positively associated with NfL (β=4.133, 95% CI: 1.705, 6.562), an effect driven primarily by systolic blood pressure. Mediation analysis revealed that hypertension accounted for approximately 15-20% of the total association between VLSFAs and NfL. Discussion: Circulating VLSFAs are inversely associated with the neurodegeneration biomarker NfL and positively correlated with cognitive performance. This neuroprotective association appears to be partially mediated by blood pressure regulation pathways. These findings identify VLSFAs as a potential therapeutic target, warranting further longitudinal and interventional studies to confirm their role in mitigating neurodegeneration.

Indexed as

hypertensionneurodegenerationNfLNHANESVLSFA

Identifiers

PMID40606500
PMCPMC12213555

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.